{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:06:25Z","timestamp":1786658785016,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/icu.0b013e3282f0ca54","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T03:01:31Z","timestamp":1192158091000},"page":"502-508","source":"Crossref","is-referenced-by-count":218,"title":["Anti-vascular endothelial growth factor therapy for ocular neovascular disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Christopher M","family":"Andreoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan W","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210206","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-11-20210206","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"R3-11-20210206","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"R5-11-20210206","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3816\/CCC.2004.s.013","article-title":"Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity","volume":"4","author":"Konner","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"R6-11-20210206","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2337\/diabetes.54.7.2188","article-title":"The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.","volume":"54","year":"2005","journal-title":"Diabetes"},{"key":"R7-11-20210206","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-11-20210206","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1167\/iovs.05-0096","article-title":"Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema","volume":"46","author":"Strom","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-11-20210206","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"key":"R10-11-20210206","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.exer.2007.01.022","article-title":"Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye","volume":"84","author":"Wang","year":"2007","journal-title":"Exp Eye Res"},{"key":"R11-11-20210206","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"R12-11-20210206","first-page":"366","article-title":"Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor","volume":"11","author":"Kinose","year":"2005","journal-title":"Mol Vis"},{"key":"R13-11-20210206","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archopht.1973.01000050208006","article-title":"Drusen and disciform macular detachment and degeneration","volume":"90","author":"Gass","year":"1973","journal-title":"Arch Ophthalmol"},{"key":"R14-11-20210206","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R15-11-20210206","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R16-11-20210206","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archopht.1982.01030030920003","article-title":"Results of a randomized clinical trial.","volume":"100","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"R17-11-20210206","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial: VIP report no. 1.","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"R18-11-20210206","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R19-11-20210206","first-page":"1929","article-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor","volume":"37","author":"Kvanta","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-11-20210206","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.","volume":"113","author":"DAmico","year":"2006","journal-title":"Ophthalmology"},{"key":"R22-11-20210206","doi-asserted-by":"crossref","first-page":"1522e1","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"key":"R23-11-20210206","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R24-11-20210206","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"R25-11-20210206","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"R26-11-20210206","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R27-11-20210206","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"key":"R28-11-20210206","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1442-9071.2006.01378.x","article-title":"Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin)","volume":"34","author":"Isaacs","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"key":"R29-11-20210206","doi-asserted-by":"crossref","first-page":"1695e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R30-11-20210206","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archopht.124.9.1365","article-title":"Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection","volume":"124","author":"Friedlander","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R31-11-20210206","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","article-title":"Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy","volume":"26","author":"Chen","year":"2006","journal-title":"Retina"},{"key":"R32-11-20210206","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.ophtha.2006.07.032","article-title":"Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy","volume":"113","author":"Aiello","year":"2006","journal-title":"Ophthalmology"},{"key":"R33-11-20210206","first-page":"1063","article-title":"Neovascular glaucoma","author":"Wand","year":"1989"},{"key":"R34-11-20210206","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0161-6420(98)92782-8","article-title":"Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma","volume":"105","author":"Tripathi","year":"1998","journal-title":"Ophthalmology"},{"key":"R35-11-20210206","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","article-title":"Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection","volume":"26","author":"Davidorf","year":"2006","journal-title":"Retina"},{"key":"R36-11-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","article-title":"Intravitreal bevacizumab in a patient with neovascular glaucoma","volume":"37","author":"Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R37-11-20210206","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.iae.0000230425.31296.3b","article-title":"Regression of neovascular iris vessels by intravitreal injection of bevacizumab","volume":"26","author":"Mason","year":"2006","journal-title":"Retina"},{"key":"R38-11-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archopht.1943.00880130054003","article-title":"Fibroblastic overgrowth of persistent tunica vasculosa lentis in premature infants. Report of cases-clinical aspects","volume":"29","author":"Terry","year":"1943","journal-title":"Arch Ophthalmol"},{"key":"R39-11-20210206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.123.3.311","article-title":"15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity","volume":"123","author":"Palmer","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R40-11-20210206","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-11-20210206","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-11-20210206","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1091-8531(97)90008-2","article-title":"Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity","volume":"1","author":"Young","year":"1997","journal-title":"J Aapos"},{"key":"R43-11-20210206","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-11-20210206","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/70963","article-title":"Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor","volume":"5","author":"Smith","year":"1999","journal-title":"Nat Med"},{"key":"R45-11-20210206","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R46-11-20210206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R49-11-20210206","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nm0103-129","article-title":"Engineered antibodies","volume":"9","author":"Hudson","year":"2003","journal-title":"Nat Med"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e3282f0ca54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:51:14Z","timestamp":1786035074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-200711000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e3282f0ca54","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}